Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs Guselkumab in Moderate-to-Severe Plaque Psoriasis
NCT03573323Phase 4Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Jul 2019
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 4, randomised, double-blind trial of ixekizumab in plaque psoriasis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants Achieving 100% Improvement From Baseline in Psoriasis Area and Severity Index at 12 weeks. Started Nov 2018; status: completed.
02
Drugs
ixekizumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03573323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573323.